Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors Hematology
Biosimilars
Global Health
Abbreviations
Tafinlar + MekinistⓇ - BRAF inhibitor and MEK inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04940052 (CDRB436J12301)
Thyroid cancer
Phase 3
150
Progression Free Survival
Arm 1: Experimental: Dabrafenib plus trametinib
Participants will be treated with dabrafenib twice daily and trametinib once daily
Arm 2: Placebo Comparator: Placebo dabrafenib plus placebo trametinib
Participants will receive placebo dabrafenib twice daily and placebo trametinib once
daily
Previously treated patients with locally advanced or metastatic, radio-active lodine
refractory BRAFV600E mutation-positive differentiated thyroid cancer
Target Patients
Read-out Milestone(s)
2024
Publication
TBD
124 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation